Results 41 to 50 of about 10,848 (199)

Obinutuzumab-Induced Inflammatory Bowel Disease-Like Colitis

Case Reports in Oncology
Introduction: Obinutuzumab, an anti-CD20 antibody, is widely used in the treatment of B-cell lymphomas. While diarrhea is a known side effect, obinutuzumab-induced inflammatory bowel disease (IBD)-like conditions are rarely reported.
Nadav Weijel, Safwat Odeh, Amjad Mousa, Nina Nazarov, Olga Zelman, Ilana Levy Yurkovski   +5 more
doaj   +1 more source

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study

HemaSphere, 2023
The phase III GALLIUM trial assessed the safety and efficacy of obinutuzumab-based versus rituximab-based immunochemotherapy in patients with previously untreated follicular lymphoma (FL) or marginal zone lymphoma (MZL).
William Townsend, Wolfgang Hiddemann, Christian Buske, Guillaume Cartron, David Cunningham, Martin J.S. Dyer, John G. Gribben, Elizabeth H. Phillips, Martin Dreyling, John F. Seymour, Andrew Grigg, Judith Trotman, Tong-Yu Lin, Xiao-Nan Hong, Dirk Kingbiel, Tina G. Nielsen, Andrea Knapp, Michael Herold, Robert Marcus   +18 more
doaj   +1 more source

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Blood
Key Points • One-year fixed-duration Ven-Obi results in durable treatment-free remissions, with a 6-year PFS rate of 53% and TTNT rate of 65%, in CLL.• End-of-treatment minimal residual disease status is associated with PFS and OS.
O. Al-Sawaf, S. Robrecht, Can Zhang, S. Olivieri, Yi-Meng Chang, A. Fink, E. Tausch, C. Schneider, M. Ritgen, K. Kreuzer, L. Sivcheva, C. Niemann, Anthony P. Schwarer, J. Loscertales, R. Weinkove, Dirk Strumberg, A. Kilfoyle, B. Manzoor, D. Jawaid, N. Emechebe, J. Devine, M. Boyer, E. Runkel, B. Eichhorst, S. Stilgenbauer, Yan-Wen Jiang, M. Hallek, K. Fischer   +27 more
semanticscholar   +1 more source

Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy

American Journal of Nephrology
Introduction: Rituximab has become the first-line therapy for patients with membranous nephropathy (MN). However, approximately 30–40% of patients with MN do not respond to rituximab.
Hui-Xian Li, Li Jin, Xinfang Xie, Ji-Ping Sun, Dan Niu, Jie Feng, Guiqing Xu, Xiaotian Zhang, Abdulrahman Majeed S. Khalaf, Wan-Hong Lu   +9 more
semanticscholar   +1 more source

The role of obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease

Clinical Kidney Journal
Background Obinutuzumab, a new-generation anti-CD20 monoclonal antibody, was originally developed to overcome resistance to rituximab in B-cell malignancies.
Zewei Chen, Dechao Xu, S. Wu, Wen-Yu Liu, Jian-Xiang Wu, Shengqiang Yu, Bing Dai, Zhi-Guo Mao, Xiang Gao   +8 more
semanticscholar   +1 more source

Obinutuzumab in Rituximab-resistant and recurrent membranous nephropathy: a case-series

JN. Journal of Nephrology (Milano. 1992)
Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults, with high risk of progression to end-stage kidney disease when untreated. Rituximab is commonly used in its treatment however many patients do not respond.
K. Sridharan, B. Gopal, Scott Wilson, Alan Pham, H. Hutton   +4 more
semanticscholar   +1 more source

Exceptional Response to Fixed Duration Obinutuzumab and Venetoclax in a Patient with Chronic Lymphocytic Leukemia: A Case Report

Case Reports in Oncology
Introduction: Obinutuzumab is a standard treatment for chronic lymphocytic leukemia (CLL) in combination with venetoclax, following the CLL-14 trial.
Maya Rosenberg, Catherine Diefenbach
doaj   +1 more source

Obinutuzumab in Rituximab-Resistant Podocytopathies: A Single-Center Experience

Kidney International Reports
1 ( a ) Indicate the study’s design with a commonly used term in the title or the ...
A. Angeletti, G. Caridi, Xhuliana Kajana, C. Bigatti, Agnese Spennacchio, D. S. Chiarenza, G. Mortari, P. Cravedi, E. Verrina   +8 more
semanticscholar   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Prospective Cohort Study of Obinutuzumab in Rituximab-Resistant Primary Membranous Nephropathy

Kidney International Reports
Introduction Approximately 30% of patients with primary membranous nephropathy (MN) and persistent nephrotic syndrome (NS) fail rituximab therapy through mechanisms that could be overcome by obinutuzumab.
M. Trillini, V. Portalupi, A. Gennarini, Livia Surdi, Annachiara Currado, M. Marasà, M. Podestà, A. Villa, Tobia Peracchi, Diego Fidone, N. Rubis, Olimpia Diadei, Chiara Guarinoni, F. Casiraghi, M. Todeschini, D. Cugini, F. Carrara, D. Martinetti, Paola Rizzo, G. Remuzzi, P. Ruggenenti   +20 more
semanticscholar   +1 more source